Biocon Ltd has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab).
Express Scripts has added Yesintek to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added Yesintek to its commercial formulary beginning on March 21, 2025. UnitedHealthcare has added Yesintek to several formularies, including commercial, beginning May 1, 2025; managed Medicaid beginning March 1, 2025; and Medicare beginning June 1, 2025. CVS Health has added Yesintek beginning July 1, 2025. And Optum Rx has added Yesintek to its Premium and Select formularies beginning July 1, 2025.
Yesintek has also been selected on several other formularies, including Navitus, Costco Health Solutions, MedImpact, Priority Health, University of Pittsburgh Medical Center (UPMC), and several other regional health plans. Additionally, Yesintek has been selected as the exclusive Ustekinumab by Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems.
The Company is also finalizing formulary agreements with other commercial carriers.
Validation of Commitment
“The strong adoption of Yesintek™ by payors in the U.S. reflects their confidence in our science, supply reliability, and commercial capability,” says Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd, in a news release. “The listing of Yesintek on multiple formularies is another validation that payors in the U.S. are committed to broaden access to affordable treatment options.”
Josh Salsi, Head of North America, Biocon Biologics Inc., adds, “More than 100 million Americans — representing 70%-80% of the commercial market — are now covered for Yesintek (ustekinumab-kfce) through commercial formularies. This marks a significant step forward in bringing high-quality, affordable biosimilars to patients managing chronic conditions.”
Yesintek is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It is available in all the same formulations currently provided by Stelara. The available presentations are 45mg/0.5mL PFS, 90mg/mL PFS, 45mg/0.5mL vial, and 130mg/26mL vial.
